ライフサイエンスコーパス: SIR

1 SIRs comprise palindromic arm sequences separated by sho

2 SIRs did not demonstrate an increased risk of malignancy

3 SIRs did not increase over time for any cancer.

4 SIRs for CUP were high in association with liver (3.94),

5 SIR = 1805), pancreatic cancer (risk = 1.5%; SIR = 256), and myeloproliferative neoplasms (risk = 0.7

6 mainly found for liver cancer (risk = 3.5%; SIR = 1805), pancreatic cancer (risk = 1.5%; SIR = 256),

7 0.2; 95% confidence interval [CI], 0.1-0.6; SIR 16%, 18/113 vs 27%, 59/220).

8 d myeloproliferative neoplasms (risk = 0.7%; SIR = 764).

9 econd cancers was similar to that in SEER 9 (SIR, 3.45; 95% CI, 0.94-8.83), although not statisticall

10 body site and expressed in terms of adjusted SIR ratios with corresponding 95% CIs.

11 termination of age-, sex-, and race-adjusted SIRs using data from a large clinical study and the SEER

12 We calculated age-, sex-, and race-adjusted SIRs, with 95% confidence intervals (CIs), using the Sur

13 After multivariable adjustment, SIRs decreased significantly across 1996-2012 for Kaposi

14 vs patients not exposed to a biologic agent (SIR, 2.17; 95% CI, 0.59-5.56), even when patients were s

15 All SIRs decreased steeply in the course of follow-up time.

16 All SIRs decreased systematically from age below 60 years to

17 No increased risk followed surgery alone (SIR, 0.93; 95% CI, 0.76 to 1.14; n = 99 solid cancers),

18 ty, for males and females and females alone, SIRs were 2.00 (P = .04) and 3.33 (P = .006).

19 re observed for acute myeloid leukemia (AML; SIR = 4.9) in Germany and for kidney cancer (2.3), AML (

20 melanoma that could be used to calculate an SIR or SMR in any flight-based occupation.

21 We introduce the framework by developing an SIR model on a simple network as an example.

22 results demonstrate that pFUS+MB induces an SIR compatible with ischemia or mild traumatic brain inj

23 istine on alternating weeks (EMA-CO) with an SIR of 0.9 (95% CI, 0.4 to 2.2), but there were signific

24 survivors (SIR = 5.3; 95% CI, 3.6 to 7.8 and SIR = 4.1; 95% CI, 2.4 to 6.9, respectively).

25 ts compliant with early CNI minimization and SIR maintenance achieved better long-term renal outcomes

26 with concomitant early CNI minimization and SIR treatment >= year 1 with significantly superior esti

27 g SIS (Susceptible-Infected-Susceptible) and SIR (Susceptible-Infected-Recovered) dynamics we investi

28 [SIR 4.90 (95% CI 3.62-6.47) 1-<5 years and SIR 4.57 (95% CI 3.44-5.95) >=15 years after surgery].

29 [SIR 6.09 (95% CI 4.39-8.23) 1-<5 years and SIR = 5.27 (95% CI 3.73-7.23) >=15 years].

30 ts of these filaments to prove that they are SIR-nucleosome filaments.

31 perfusion rates (21%, 48%, and 77% for ASITN/SIR grades of 0 or 1, 2, and 3 or 4, respectively; P < .

32 e MCA territory (32%, 48%, and 69% for ASITN/SIR grades of 0 or 1, 2, and 3 or 4, respectively; P < .

33 linical outcome (11%, 35%, and 49% for ASITN/SIR grades of 0 or 1, 2, and 3 or 4, respectively; P = .

34 Nineteen patients had ASITN/SIR collateral vessel grades of 0 or 1, 63 patients had

35 cal outcome, with 53% of patients with ASITN/SIR grades of 3 or 4 having a good outcome, as compared

36 O-EA), reduces proton irradiation-associated SIR and tumorigenesis.

37 onclude by outlining strategies to attenuate SIR, including approaches to rejuvenate HSCs, which may

38 s study, a general adapted time-window based SIR prediction model is proposed, which is characterized

39 Differences between SIRs were assessed using multivariate negative binomial

40 sus body and extremity tumors for both bone (SIR, 2,213; 95% CI, 1,671 to 2,873 v SIR, 169; 95% CI, 1

41 The highest SIRs were for SMNs of bones (SIR, 28.8), oral cavity (SIR, 13.8), skin (SIR, 7.3), ce

42 CI, 5.84 to 10.07), specifically for breast (SIR, 8.92; 95% CI, 5.85 to 13.07), thyroid (SIR, 5.83; 9

43 Prevention of CNI nephrotoxicity by SIR-based early CNI minimization protects renal function

44 SMNs, risk was increased for breast cancer (SIR, 5.5; 95% CI, 4.5 to 6.7), renal cancer (SIR, 3.9; 9

45 timated among survivors of laryngeal cancer (SIR, 1.75 [95% CI, 1.68-1.83]; incidence, 373 per 10 000

46 en, and among survivors of laryngeal cancer (SIR, 2.48 [95% CI, 2.27-2.72]; incidence, 336 per 10 000

47 SIR, 5.5; 95% CI, 4.5 to 6.7), renal cancer (SIR, 3.9; 95% CI, 2.0 to 7.5), soft tissue sarcoma (SIR,

48 .6; 95% CI, 1.5 to 4.4), and thyroid cancer (SIR, 1.9; 95% CI, 1.0 to 3.5).

49 was significantly elevated for all cancers (SIR, 7.74; 95% CI, 5.84 to 10.07), specifically for brea

50 latter particularly in rob(15;21) carriers (SIR = 447.8, 95% CI: 11.3, 2,495).

51 for SMNs of bones (SIR, 28.8), oral cavity (SIR, 13.8), skin (SIR, 7.3), central nervous system (SIR

52 behavior at larger scales mirrors a classic SIR-like pattern.

53 The shift from the classical SIR framework to one incorporating the environment requi

54 isk of all types of second cancers combined (SIR, 3.40; 95% CI, 1.55-6.45), particularly lymphoma (SI

55 for COVID-19 employ variants of compartment (SIR or susceptible-infectious-recovered) models at local

56 We consider SIR and SIS propagation dynamics on a temporally-extrude

57 n recipients with cholestatic liver disease (SIR 2.78); five of these cases had primary biliary cirrh

58 CI 1.40-2.93) or with high-grade dysplasia (SIR 0.79; 95% CI 0.39-1.41), whereas for individuals wit

59 Persistently elevated SIRs along with decreasing absolute rates over the entir

60 Significantly elevated SIRs of specific SPCs were observed for acute myeloid le

61 Significantly elevated SIRs were observed for NMSC and NHL in those treated wit

62 k of invasive melanoma (n=519) was elevated (SIR=2.20, 95% CI 2.01-2.39), especially for regional sta

63 on model based on mathematical epidemiology (SIR) is the most widely used, but most of these models a

64 We estimated SIR and odds ratios (OR) to assess risk factors for seco

65 0.06 to 0.14]) than low-quality examination (SIR, 0.32 [CI, 0.29 to 0.35]; SMR, 0.22 [CI, 0.18 to 0.2

66 hereas significantly increased 40% excesses (SIR, 1.43; 95% CI, 1.18 to 1.73; n = 111 solid cancers)

67 agent methotrexate and folinic acid (MTX-FA; SIR, 0.7; 95% CI, 0.5 to 1.1) and also for patients trea

68 diation (median, 40 Gy) to the mantle field (SIR, 24.2; 95% CI, 20.7 to 28.3).

69 Recently, for SIR-type infections (that produce one epidemic in a clos

70 Further, SIR-PAM achieves 1.5 times finer lateral resolution than

71 primary invasive melanoma also on the head (SIR, 13.32; 95% CI, 10.28-16.98).

72 The highest SIRs were for SMNs of bones (SIR, 28.8), oral cavity (SI

73 ks were increased after 27 AIds; the highest SIRs were noted for chorea minor (8.00), lupoid hepatiti

74 between myopenia, myosteatosis, and the host SIR in patients with operable CRC.

75 Our results thus highlight how SIR can be used to investigate the component processes o

76 of malignancy among patients exposed to IFX (SIR, 1.69; 95% CI, 0.46-4.32) vs patients not exposed to

77 To realize motionless volumetric imaging, SIR-PAM combines two-dimensional Fourier-spectrum optica

78 , leading to further sulfite accumulation in SIR Ri plants.

79 y invasive melanomas diagnosed, resulting in SIRs of 5.42 (95% CI, 5.23-5.61) and 4.59 (4.37-4.82) fo

80 tion resulted in 2-fold lower CRC incidence (SIR, 0.16 [CI, 0.13 to 0.20]) and mortality (SMR, 0.10 [

81 Factors associated with increased SIR included index age group 1-4 years (OR 3.6; 95% CI,

82 occurrence of second UM was also increased (SIR = 16.90, 95% CI: 9.00-28.90), which likely includes

83 tatistically significant trend of increasing SIRs with increasing number of melanomas in relatives.

84 Initial SIR calculations for white females of all ages was 1.15

85 ired SiR expression due to RNA interference (SIR Ri) developed early leaf senescence.

86 95% CI: 1.01, 3.24) and childhood leukemia (SIR = 14.5, 95% CI: 1.75, 52.2), the latter particularly

87 adenoma characteristics the risk was lower (SIR 0.35; 95% CI 0.28-0.44).

88 ; 95% CI, 1.55-6.45), particularly lymphoma (SIR, 12.86; 95% CI, 2.65-37.59) and melanoma (SIR, 9.31;

89 h the general population for any malignancy (SIR, 4.39; 95% CI, 2.78-6.59) and for any malignancy exc

90 IR, 12.86; 95% CI, 2.65-37.59) and melanoma (SIR, 9.31; 95% CI, 8.75-33.62).

91 first 5-year follow-up after first melanoma: SIR of 6.1 (95% CI, 4.0-9.0) for interval up to 1 year,

92 nificantly increased risk of skin melanomas (SIR = 2.93, 95% CI: 2.23-3.78) and kidney tumors (SIR =

93 variant resolution photoacoustic microscopy (SIR-PAM).

94 6.59) and for any malignancy excluding NMSC (SIR, 4.16; 95% CI, 1.67-8.57).

95 aditionally associated with NF1, we observed SIRs of 2,056 (95% CI, 1,561 to 2,658), and 37.5 (95% CI

96 multivariable Poisson regression analysis of SIR ratios, adjusting for 5-year time period of transpla

97 visual chlorophyll degradation in leaves of SIR Ri mutants was accompanied by a reduction of maximal

98 The presence of SIR was evidenced by the modified Glasgow prognostic sco

99 aphy of silenced chromatin, and the roles of SIR and RNA interference (RNAi) genes in T. delbrueckii.

100 After proton irradiation, a subset of SIR genes (Troy, Sox17, Opg, Faim2, Lpo, Tlr2 and Ptges)

101 lencing that extends even beyond the zone of SIR binding.

102 eased mutability is an intrinsic property of SIRs as evidenced by how almost all mutational processes

103 ous system (SIR, 6.0), and endocrine organs (SIR, 4.9).

104 3 were diagnosed with T2D, giving an overall SIR for T2D of 1.66.

105 The highest overall SIR and SMR were estimated among survivors of laryngeal

106 was higher in HIV-infected patients (overall SIR, 2.7; 95% CI, 2.6-2.9), particularly those aged 15-4

107 The overall SIR for hospitalization for sepsis was 5.7 [95% confiden

108 The overall SIR remained increased twofold after 1 or more years of

109 The overall SIR was 3.2 (95% confidence interval [CI], 2.8-3.6) but

110 Particularly high overall SIRs were observed in patients with NF1 age < 15 years:

111 The overall SIRs and HRs of the combined outcome laryngeal or pharyn

112 vated (p<0.0001 for all) for cancer overall (SIR 1.69, 95% CI 1.67-1.72), AIDS-defining cancers (Kapo

113 cess of HPV-associated malignancies overall (SIR = 1.4, 95% CL: 1.2, 1.8).

114 SIR, 5.01 [CI, 3.30 to 7.62]) than a parent (SIR, 1.96 [CI, 1.45 to 2.67]; interaction P < 0.0001).

115 In particular, SIR was 11.1 (95% CI, 5.56 to 19.5) for breast cancer in

116 fy independent relationships between patient SIR and muscle characteristics.

117 s elevated vs the general population (pooled SIR = 6.8, 95% confidence interval [CI], 4.3-10.9; 6 stu

118 s lower than that of the general population (SIR 0.51, 95% CI 0.29-0.84).

119 antly higher than in the general population (SIR 1.30, 95% CI 1.06-1.57).

120 tients compared with the general population (SIR [95% confidence interval], 25.4 [11.4-56.4] and 6.7

121 fferent from that in the general population (SIR, 1.01 [95% CI, 0.93-1.09]) and from the risk in the

122 in younger people in the general population, SIRs were highest in younger transplant recipients (p =

123 (ASITN)/Society of Interventional Radiology (SIR) collateral vessel grading system, while reperfusion

124 mate the household secondary infection rate (SIR) to inform strategies to reduce transmission.

125 gkin lymphoma (standardized incidence ratio (SIR) = 1.90, 95% CI: 1.01, 3.24) and childhood leukemia

126 person-years; standardized incidence ratio (SIR) and standardized mortality ratio (SMR) compared wit

127 Standard incidence ratio (SIR) calculations were provided by the respective states

128 by calculating the standard incidence ratio (SIR) comparing observed cancer incidence in patients wit

129 eady decline in standarized incidence ratio (SIR) for both sexes.

130 resulting in a standardized incidence ratio (SIR) of 4.6 (95% confidence interval [CI], 4.3 to 4.9) i

131 ion rates, the standardized incidence ratio (SIR) of SMNs was increased 2.8-fold.

132 hat reported a standardized incidence ratio (SIR), standardized mortality ratio (SMR), or data on exp

133 m in diameter (standardized incidence ratio [SIR] 2.07; 95% CI 1.40-2.93) or with high-grade dysplasi

134 t cancer risk (standardized incidence ratio [SIR] = 4.0; 95% CI, 3.0 to 5.3) was observed when compar

135 e of anal SCC (standardized incidence ratio [SIR] vs general population, and absolute incidence rate

136 number of 79 (standardized incidence ratio [SIR], 1.1; 95% CI, 0.9 to 1.3).

137 s a threefold (standardized incidence ratio [SIR], 3.3; 95% confidence interval [CI], 2.8-3.9) increa

138 breast cancer (standardized incidence ratio [SIR], 43.6; 95% CI, 27.2 to 70.3), as did survivors trea

139 gren syndrome (Standardized incidence ratio [SIR]8.14), scleroderma (SIR 7.00), rheumatoid arthritis

140 Standardized incidence ratios (SIR) and 95% confidence intervals were calculated and mu

141 We obtained standardized incidence ratios (SIR) and excess absolute risks of SPNs on patients with

142 risk-adjusted standardized infection ratios (SIR) to assess the impact of comorbidity adjustment on p

143 oma risk with standardized incidence ratios (SIRs) and cumulative incidence analyses.

144 Standardized incidence ratios (SIRs) and standardized mortality ratios (SMRs) of CRC af

145 Standardized incidence ratios (SIRs) and standardized mortality ratios (SMRs) were calc

146 expressed as standardized incidence ratios (SIRs) and standardized mortality ratios (SMRs).

147 The standardized incidence ratios (SIRs) and the 5- and 10-year incidence rates were estima

148 nalyzed using standardized incidence ratios (SIRs) and, for SCC, multivariable Poisson regression ana

149 Standardized incidence ratios (SIRs) expressing risk of next melanoma by calculating th

150 Standardized incidence ratios (SIRs) for all SMNs combined and for breast, thyroid, end

151 Standardized incidence ratios (SIRs) for cancer were calculated after the last medical

152 sex-adjusted standardized incidence ratios (SIRs) for CRC in both groups, as well as in their first-

153 Standardized incidence ratios (SIRs) for senile cataract was significantly increased to

154 Standardized incidence ratios (SIRs) for solid tumors were calculated for 12,691 patien

155 The standardized incidence ratios (SIRs) of autism and ADHD among individuals with a biolog

156 The standardized incidence ratios (SIRs) of diffuse large B-cell lymphoma (DLBCL) and folli

157 ncidence, and standardised incidence ratios (SIRs) of primary cases (ie, excluding relapses) based on

158 to calculate standardized incidence ratios (SIRs) of S aureus bacteremia, with the incidence rate in

159 We used standardized incidence ratios (SIRs) to compare incidence with the general population a

160 nd calculated standardised incidence ratios (SIRs) to measure cancer risk in people with HIV compared

161 incidence and standardised incidence ratios (SIRs) using as standard the general population of Englan

162 Standardized incidence ratios (SIRs) were calculated by malignancy type.

163 Standardized incidence ratios (SIRs) were calculated for CUP patients defined by metast

164 Familial standardized incidence ratios (SIRs) were calculated for offspring whose parents or sib

165 Standardized incidence ratios (SIRs) were calculated for other tumors in patients who h

166 Standardized incidence ratios (SIRs) were calculated for T2D diagnosis in patients with

167 Standardized incidence ratios (SIRs) were calculated to estimate risks for other Lynch

168 Age- and sex-standardized incidence ratios (SIRs) were estimated by race.

169 incidence and standardized incidence ratios (SIRs) were estimated by treatment: chemotherapy-only (n

170 Standardized incidence ratios (SIRs) were used for comparison with the general populati

171 Standardized incidence ratios (SIRs) were used to assess risk of a specific SPC compare

172 y calculating standardized incidence ratios (SIRs) with 95% confidence intervals (95% CIs).

173 y calculating standardized incidence ratios (SIRs) with 95% confidence intervals (CIs).

174 Standardized incidence ratios (SIRs), a proxy measure for relative risk, were calculate

175 dence of SNs, standardized incidence ratios (SIRs), excess absolute risk of subsequent malignant neop

176 nd calculated standardized incidence ratios (SIRs).

177 ute risks and standardized incidence ratios (SIRs).

178 l population (standardized incidence ratios [SIRs]) and the non-IVF group (hazard ratios [HRs]).

179 We use reconstituted SIR heterochromatin to characterize the steps in transcr

180 as carried out using selected ion recording (SIR) acquisition mode.

181 pectrometry (MS/MS), selected ion recording (SIR) and multiple reaction monitoring (MRM) and identifi

182 thm with the susceptible-infected-recovered (SIR) compartmental model to simulate the evolution of EV

183 The Susceptible-Infected-Recovered (SIR) model has successfully mimicked the propagation of

184 e a modified susceptible-infected-recovered (SIR) model in the United States.

185 studying the susceptible-infected-recovered (SIR) model on uncorrelated configuration networks and a

186 ction with a susceptible-infected-recovered (SIR) model.

187 e well-known susceptible-infected-recovered (SIR) model.

188 e.g., as in susceptible-infected-recovered (SIR) models.

189 lyses of the Susceptible-Infected-Recovered (SIR) spreading dynamics on fourteen real networks show t

190 We use a susceptible-infectious-recovered (SIR) model for two coupled populations to make the conce

191 We use a susceptible-infectious-recovered (SIR) model in conjunction with an ensemble adjustment Ka

192 The Susceptible-Infectious-Recovered (SIR) model is known to have an exact semi-analytical sol

193 we show a Susceptible-Infectious-Recovered (SIR) model modified to include control measures that all

194 A Susceptible-Infectious-Recovered (SIR) model was adopted to calculate the effective reprod

195 and cp and in the short intergenic regions (SIR).

196 urability depends on the metabolic regulator SIR-2.1, a NAD(+)-dependent histone deacetylase.

197 gulated by the silent information regulator (SIR) complex.

198 tone-modifying silent information regulator (SIR) complex.

199 07, and 2008-2012 periods, with the relative SIRs being 0.42 (95% CI, 0.32-0.55), 0.31 (95% CI, 0.22-

200 observed among these first-degree relatives (SIR, 2.49 [95% CI, 1.95 to 3.19]) than in the background

201 referred to as senescent immune remodeling (SIR).

202 A susceptible-infected-removed (SIR) model with confinement (SCIR) illustrates how lockd

203 lications to Susceptible-Infectious-Removed (SIR) dynamics).

204 ive sequences termed short inverted repeats (SIRs) have the propensity to form secondary DNA structur

205 veloped stimulus information representation (SIR), an information theoretic framework, to tease apart

206 ters and the systemic inflammatory response (SIR) in patients with operable primary colorectal cancer

207 dicative of a sterile inflammatory response (SIR) in the parenchyma.

208 an elevated systemic inflammatory response (SIR) is associated with reduced survival in patients wit

209 atus (MUST), systemic inflammatory response (SIR), body composition, and clinical outcomes in patient

210 enescence-associated inflammatory responses (SIRs), which are involved in colon cancer initiation and

211 4) carriers had a higher breast cancer risk (SIR = 1.58, 95% CI: 1.12, 2.15).

212 ated the household secondary infection risk (SIR) and serial interval (SI) for influenza transmission

213 9; 95% CI, 2.0 to 7.5), soft tissue sarcoma (SIR, 2.6; 95% CI, 1.5 to 4.4), and thyroid cancer (SIR,

214 5% CI, 115 to 239) and soft-tissue sarcomas (SIR, 542; 95% CI, 418 to 692 v SIR, 45.7; 95% CI, 31.1 t

215 nt: the "2010 ACCF/AHA/AATS/ACR/ASA/SCA/SCAI/SIR/STS/SVM Guidelines for the Diagnosis and Management

216 zed incidence ratio [SIR]8.14), scleroderma (SIR 7.00), rheumatoid arthritis (SIR5.96), stillbirth (S

217 her if the index case patient was a sibling (SIR, 5.01 [CI, 3.30 to 7.62]) than a parent (SIR, 1.96 [

218 Significant SIRs were observed for cancers of the small bowel, ovari

219 were at least two independently significant SIRs or a statistically significant trend of increasing

220 ian target of rapamycin inhibitor Sirolimus (SIR) within 4-6 weeks after LT (group B, n = 261).

221 eneration models, activation of the Sirtuin, SIR-2.1, was not required, as sir-2.1; dnj-14 double mut

222 (SIR, 28.8), oral cavity (SIR, 13.8), skin (SIR, 7.3), central nervous system (SIR, 6.0), and endocr

223 5% CI, 3.01 to 10.18), and endometrial SMNs (SIR, 14.08.07; 95% CI, 7.10 to 27.21).

224 In contrast to a standard SIR model, we find that the incidence of COVID-19 spread

225 es in the US, but inconsistent with standard SIR modeling.

226 We then explore its use on the stochastic SIR model to predict the final size distribution and inf

227 -effect meta-analyses were used to summarize SIR and SMR for melanoma in any flight-based occupation.

228 Summary SIR and SMR of melanoma in pilots and cabin crew.

229 The overall summary SIR of participants in any flight-based occupation was 2

230 The summary SIR for cabin crew was 2.09 (95% CI, 1.67-2.62; P = .45;

231 The summary SIR for pilots was 2.22 (95% CI, 1.67-2.93; P = .001; 12

232 hagitis or Barrett esophagus) after surgery [SIR 6.09 (95% CI 4.39-8.23) 1-<5 years and SIR = 5.27 (9

233 k did not decrease after antireflux surgery [SIR 4.90 (95% CI 3.62-6.47) 1-<5 years and SIR 4.57 (95%

234 ecreased >10 years after antireflux surgery [SIR = 0.28 (95% CI 0.08-0.72) and HR = 0.23 (95% CI 0.08

235 ecreased >10 years after antireflux surgery [SIR = 0.48 (95% CI 0.26-0.80) and HR = 0.47 (95% CI 0.26

236 39) were decreased after antireflux surgery [SIR = 0.62 (95% CI 0.44-0.85) and HR = 0.55 (95% CI 0.38

237 ighest among sarcoma and leukemia survivors (SIR = 5.3; 95% CI, 3.6 to 7.8 and SIR = 4.1; 95% CI, 2.4

238 8), skin (SIR, 7.3), central nervous system (SIR, 6.0), and endocrine organs (SIR, 4.9).

239 Cs, which may open new avenues for targeting SIR in the clinic.

240 We tested SIR differences by AIDS status and over time using Poiss

241 Here, we show that SIRs confer an increase in localized mutability in breas

242 The SIR calculations considering the observed and expected i

243 The SIR complex cannot erase H2B-Ub or histone methylation o

244 The SIR complex comprises the NAD-dependent deacetylase Sir2

245 The SIR did not increase with longer time since treatment (>

246 The SIR for CRC also did not differ significantly between fi

247 The SIR for CRC in patients with serrated polyposis (0.51; 9

248 The SIR for glaucoma was 1.60 after MGUS, 1.76 after WM and

249 The SIR has independent prognostic value, across tumour type

250 The SIR was 1.40 (95% CI, 0.72-2.45) in males and 1.37 (95%

251 The SIR was 1.63 for CUP with metastases in the abdomen when

252 The SIR was 29% (n = 55/188; 95% confidence interval [CI]: 2

253 The SIR was 9.21 [95% confidence interval (CI), 1.85-26.91]

254 The SIR was quantified by the preoperative neutrophil to lym

255 the 1980s, as in the decade 2000 to 2010 the SIR increased to 1.13 (95% CI, 1.07-1.19) for men and 1.

256 Although the SIR model has recently been studied in a multilayer netw

257 rized the interactions between Ubp10 and the SIR complex machinery.

258 re-reviewed by a hematopathologist, and the SIR for NLPHL was calculated on the basis of confirmed N

259 The 3-month cancer risk was 8.0% and the SIR was 33 (95% confidence interval, 27-40), compared wi

260 el curves have nearly the same shapes as the SIR ones, but with a stretch factor applied to them acro

261 Only after high-quality colonoscopy did the SIR and SMR for 10.1 to 17.4 years of follow-up not diff

262 diagnosed >/= 6 months after enrollment, the SIR for all cancers decreased to 1.06 (95% CI: 0.94, 1.1

263 -2.82) did not differ significantly from the SIR for CRC in patients with multiple serrated polyps (0

264 on was preserved at 3 months after LT in the SIR arm (estimated glomerular filtration rate 74 [57-95]

265 age, graft organ, and sex, a decline in the SIR for SCC was found, with SIR peaking in patients who

266 tion, we reveal that magnesium exists in the SIR-nucleosome filament, with a role similar to that for

267 ; for example, for 2 previous melanomas, the SIR was 2.8 (95% CI, 2.3-3.4) for patients with familial

268 e biochemistry and structural biology of the SIR-chromatin system bring us much closer to a molecular

269 ate that cohesin operates independent of the SIR-mediated pathway for telomeric silencing.

270 localization patterns of Sir proteins on the SIR-nucleosome filament reflect those patterns on telome

271 The data and EAKF are used to optimize the SIR model and i) estimate critical epidemiological param

272 btelomeric repressed domains lie outside the SIR-binding region, but the mechanism of silencing in th

273 In the California Cancer Registry, the SIR for risk of all types of second cancers was similar

274 siae, heterochromatin formation requires the SIR complex, which contains subunits with histone-modify

275 Although most of the conclusions that the SIR does not meet statistical criteria that defines thes

276 he proteomic findings and indicated that the SIR was facilitated through the induction of the NFkappa

277 The SIRs remained elevated throughout the follow-up period.

278 Finally, we tested the SIRs for global and local spatial autocorrelation to ide

279 (SIR, 8.92; 95% CI, 5.85 to 13.07), thyroid (SIR, 5.83; 95% CI, 3.01 to 10.18), and endometrial SMNs

280 onally active regions present a challenge to SIR complex-mediated de novo heterochromatic silencing d

281 ll (HSC) compartment directly contributes to SIR due to aging-associated alterations in stem cell dif

282 l elevated 35 years or more after treatment (SIR, 3.9; 95% CI, 2.8 to 5.4), and the cumulative incide

283 2.93, 95% CI: 2.23-3.78) and kidney tumors (SIR = 1.91, 95% CI: 1.27-2.76), primarily in those diagn

284 2.39), especially for regional stage tumors (SIR=4.11, 95% CI 3.27-5.09).

285 tion in the 1983-1987 period, the unadjusted SIR for SCC was 102.7 (95%, 85.8-122.1), declining to 21

286 cellular and molecular mechanisms underlying SIR.

287 Our findings provide evidence for a unique SIR-independent mechanism of subtelomeric repression med

288 melanoma within the first year of follow-up (SIR, 5.3 [95% CI, 4.3-6.4]) and afterward remained stead

289 Using SIR, we demonstrate that a rapid (~170 ms) reduction of

290 sue sarcomas (SIR, 542; 95% CI, 418 to 692 v SIR, 45.7; 95% CI, 31.1 to 64.9).

291 h bone (SIR, 2,213; 95% CI, 1,671 to 2,873 v SIR, 169; 95% CI, 115 to 239) and soft-tissue sarcomas (

292 lly derepressed in a cohesin mutant, whereas SIR binding was unaltered.

293 Factors associated with SIR were evaluated using logistic regression.

294 a decline in the SIR for SCC was found, with SIR peaking in patients who underwent transplantation in

295 eneral population (95% CI, 2.5 to 3.2), with SIRs increased for subsequent leukemia/lymphoma (1.9; 95

296 nded on the indication for splenectomy, with SIRs varying from 3.4 (95% CI, 3.0-3.8) for trauma patie

297 ceive a diagnosis of SMN after age 40 years (SIR, 2.2; 95% CI, 1.9 to 2.5).

298 ceived a diagnosis at younger than 40 years (SIR, 4.7 [95% CI, 3.9-5.6]), and we found a notable risk

299 6-2.9), particularly those aged 15-44 years (SIR, 4-6).

300 In New York, SIR for Broome and Tioga counties were 0.93 and not sign